11/21/2024

Janusmed kön och genus

Janusmed kön och genus – eprosartan

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Eprosartan

Eprosartan

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR et al. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17(9):2554-60.

  2. Teveten (eprosartan). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-09-16, cited 2021-02-10]

  3. Food and Drug Administration (FDA). Prescribing information - Teveten HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2014-07-22, cited 2021-02-10].

  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - TEVETEN HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2001-05-24, cited 2021-02-10].

  5. de la Sierra A, Munoz A, Arcos E, Lopez JS, Relats J, Investigators of the Etapa-II Study. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press Suppl. 2004;2:5-10.

  6. Hedner T. Management of hypertension: the advent of a new angiotensin II receptor antagonist. J Hypertens Suppl. 1999;17(2):S21-5.

  7. Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension Eprosartan Study Group. Clin Ther. 1999;21(3):442-53.

  8. Punzi, HA and Punzi, CF. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Hum Hypertens. 2004;18(9):655-61.

  9. Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16(3):169-76.

  10. Food and Drug Administration (FDA). Medical review(s), part 2 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 2001-06-25, cited 2021-02-10].

  11. Food and Drug Administration (FDA). Medical review(s), part 5 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].

  12. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29(21):2669-80.

  13. Food and Drug Administration (FDA). Medical review(s), part 6 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].

  14. Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med. 2007;5:29.

  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]

  1. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR et al. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17(9):2554-60.
  2. Teveten (eprosartan). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-09-16, cited 2021-02-10]
  3. Food and Drug Administration (FDA). Prescribing information - Teveten HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2014-07-22, cited 2021-02-10].
  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - TEVETEN HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2001-05-24, cited 2021-02-10].
  5. de la Sierra A, Munoz A, Arcos E, Lopez JS, Relats J, Investigators of the Etapa-II Study. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press Suppl. 2004;2:5-10.
  6. Hedner T. Management of hypertension: the advent of a new angiotensin II receptor antagonist. J Hypertens Suppl. 1999;17(2):S21-5.
  7. Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension Eprosartan Study Group. Clin Ther. 1999;21(3):442-53.
  8. Punzi, HA and Punzi, CF. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Hum Hypertens. 2004;18(9):655-61.
  9. Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16(3):169-76.
  10. Food and Drug Administration (FDA). Medical review(s), part 2 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 2001-06-25, cited 2021-02-10].
  11. Food and Drug Administration (FDA). Medical review(s), part 5 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].
  12. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29(21):2669-80.
  13. Food and Drug Administration (FDA). Medical review(s), part 6 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].
  14. Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med. 2007;5:29.
  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]